以下文章来源于金融八卦女频道 ，作者乌彦祖假正经 金融八卦女频道 . 有深度、有温度、有态度，在这里读懂财富。 鹬蚌相争有人得利。 作者：乌彦祖假正经 来源：金融八卦女频道 医美圈都不用"暗箭"了，直接"明枪"。 网红"大嘴博士"指责港股上市公司巨子生物"疑似造假"的舆论战，正式升级为两家医美巨头 的"大乱斗"。 6月1日晚19:30分，华熙生物发布文章《关于支持郝宇博士维护消费者权益的声明》，称跟郝 宇（"大嘴博士"）有商业合作，支持他、保护他。同时喊话："汝求战，便得战!" 3个小时后，巨子生物开始"应战"：5月30日收到"大嘴博士"（郝宇）所用检测机构的道歉声 明，严令禁止大嘴博士使用这个《检测报告》。 到底什么仇，什么怨，让两家上市公司唇枪舌战？ 2021年以来，华熙生物看家法宝"玻尿酸"在资本市场上被冷落，销量和股价都在下降，而巨 子生物的"重组胶原蛋白"却风生水起，一直涨不停。按照双方声明透露的信息，这期间，私下 没少"互射冷箭"。 网红"打假"上市公司， 竟扯出两位"医美女王"的多年暗战？ 华熙生物跟巨子生物的争端早有"预兆"。 5月17日都快深夜12点了，昔日"医美茅"华熙生物突然发布了一篇言 ...

Core Insights - Zhao Yan, known as the "Hyaluronic Acid Queen," has built a significant business empire and holds a crucial position in the capital market and industry [2] - The journey of Zhao Yan from a university assistant to a successful entrepreneur is marked by challenges and strategic decisions that led to her current success [2][3] Early Career and Initial Ventures - Zhao Yan was born in 1966 in Kunming, Yunnan, and showed exceptional academic talent, leading her to East China Normal University [2] - After graduating in 1986, she worked as a teaching assistant with a modest salary of less than 100 yuan per month [2] - In 1988, she left her stable job to pursue opportunities in Hainan, pooling 5,000 yuan with three other teachers to start a business [2][3] First Major Success - Zhao Yan discovered an opportunity with a joint venture factory in Hainan that had unsold refrigerators, which she and her partners repaired and sold, earning a profit of 800,000 yuan [3] - This initial success allowed them to invest in a clothing factory, which generated annual revenue of 1 million yuan [5] Real Estate Investments - Recognizing the potential in Hainan's real estate market, Zhao Yan used profits from the clothing business to acquire properties, leading to a wealth increase from 800,000 yuan to 2 million yuan [5] - She eventually sold her real estate holdings at the peak of the market, successfully avoiding the subsequent market crash [8] Expansion to Beijing and Real Estate Development - After relocating to Beijing, Zhao Yan founded Huaxi Group and developed significant projects, including Huaxia Bank Tower and Wukesong Sports Center, contributing to the company's total assets exceeding 80 billion yuan [9] Entry into Biopharmaceuticals - In the early 2000s, Zhao Yan invested in Shandong Furuida Biological Chemical Co., becoming the largest shareholder and later rebranding it as Huaxi Biological [11] - Under her leadership, the company became the world's largest producer of hyaluronic acid by 2007, expanding into medical aesthetics and functional skincare products [12] Product Diversification and Market Expansion - Huaxi Biological launched various medical aesthetic products, including hyaluronic acid fillers and functional skincare lines, achieving high market share and positive consumer reception [12][13] - In 2021, the company introduced functional foods like hyaluronic acid drinking water, capitalizing on the growing health-conscious consumer trend [15] Cultural and Social Contributions - Zhao Yan's leadership extended to cultural projects, such as the development of Wukesong Sports Center, which hosted major events like the 2008 Beijing Olympics [15] - The establishment of Huaxi International Era Art Museum has contributed significantly to the promotion of Chinese cultural and artistic endeavors [16] Future Outlook - Huaxi Biological stands at a new crossroads with a leading position in hyaluronic acid production, a growing skincare brand portfolio, and ambitious plans in synthetic biology [18] - Zhao Yan faces ongoing challenges in balancing marketing, technology, and corporate responsibilities as the leader of a public company [18]

Core Viewpoint - The ongoing controversy surrounding the collagen product from Juzhibio's brand Kefu Mei highlights a significant conflict between two major players in the medical beauty industry, Juzhibio and Huaxi Biological, which may represent a deeper technical rivalry between recombinant collagen and hyaluronic acid [1][2]. Group 1: Company Actions and Responses - Juzhibio confirmed that its Kefu Mei Human-like recombinant collagen essence contains more than 0.1% recombinant collagen, countering claims made by beauty blogger "Big Mouth Doctor" that the actual content was only 0.0177% [1]. - Following the allegations, Huaxi Biological publicly supported the claims made by the beauty blogger, escalating the conflict between the two companies [1]. - The dispute has led to a series of emotional exchanges between the companies, with accusations of malicious competition and misinformation being exchanged [2]. Group 2: Consumer Concerns and Industry Implications - Consumers are primarily concerned about the quality and compliance of the medical beauty products rather than the corporate disputes, indicating a need for clarity and assurance regarding product safety [2]. - The controversy has overshadowed scientific standards, with conflicting reports and a lack of consensus on the testing methods used, leading to confusion among consumers [2][3]. - The ongoing conflict reflects deeper issues within the medical beauty industry, such as unclear product standards and marketing boundaries, which have allowed for such disputes to arise [3]. Group 3: Regulatory and Industry Response - The situation calls for neutral arbitration from regulatory bodies to investigate the claims and provide credible testing reports to resolve the dispute and restore consumer trust [2]. - The market regulatory authorities have issued guidelines to strengthen oversight of the medical beauty industry, aiming to address long-standing issues such as false advertising and lack of transparency [3]. - This public incident could serve as an opportunity for the industry to establish clearer standards and regulations, ultimately benefiting both the sector and consumers [3].

随着事件进一步发酵升级，背后隐藏的技术路线之争与行业标准缺失问题也浮出水面。一位化妆品行业 人士直指，巨子生物和华熙生物的"开撕"，本质是两家企业对市场份额和行业主导权的争夺。 昨晚，巨子生物发布最新回应，并公布了多家权威检测机构的检测数据：经多个检测机构对多批次"胶 原棒"进行检测分析，确认产品中重组胶原蛋白含量均大于0.1%。巨子生物强调，可复美相关产品不存 在"虚假宣传"的行为。同时，可复美胶原棒1.0版本因售罄陆续下架，并非网传的"悄悄下架"。 近几年，凭借核心护肤品牌可复美，巨子生物的业绩节节攀升，2024年可复美品牌贡献45.4亿元，营收 占比达到82%。然而，巨子生物也多次因产品成分陷入争议，舆论风波使得公司的品牌公信力受到严峻 考验。 检测报告引爆争议，巨子生物最新回应 巨子生物与华熙生物"开撕"的导火索源于香港大学化学博士"大嘴博士"郝宇发布的检测报告。 文 | 新浪财经 徐苑蕾 国内医美行业正经历一场"成分风暴"。 近日，业内两大巨头——巨子生物与华熙生物因"重组胶原蛋白"真实含量问题爆发激烈争议，从产品成 分质疑升级至公开"商战"。在618大促的关键节点，涉事产品可复美"胶原棒"1.0版 ...

Core Viewpoint - The controversy surrounding the collagen content in the product "Kefumei" from Giant Biological has raised significant consumer and investor concerns, with ongoing debates about the accuracy of testing methods and results [1][10]. Group 1: Testing Results - Giant Biological confirmed that the "Kefumei Human-like Recombinant Collagen Essence" contains recombinant collagen, with content levels greater than 0.1% as per third-party testing [2][10]. - The testing utilized two methods: LC-MS/MS for qualitative analysis and the Biuret method for quantitative analysis, with results showing collagen content of 0.2%, 0.22%, and 0.2% across three batches [2][8]. - A subsequent test on one batch indicated a collagen content of 0.17%, confirming that the product meets the stated requirements [8][9]. Group 2: Consumer Concerns and Responses - The initial claim by beauty blogger "Big Mouth Doctor" suggested that the actual collagen content was only 0.0177%, leading to widespread skepticism about the product's integrity [10][11]. - Giant Biological emphasized that there is no misleading advertising and that the product has been properly tested, countering claims of "quietly delisting" the product due to sales issues [10][11]. - The company expressed concern over consumer anxiety caused by misinformation and reiterated its commitment to transparency and product integrity [10][11]. Group 3: Industry Reactions - Huaxi Biological publicly supported the claims made by "Big Mouth Doctor," indicating that they have conducted their own evaluations and testing of the product [11][14]. - Huaxi Biological criticized Giant Biological for alleged unethical marketing practices and indicated readiness to engage in a public discourse regarding product integrity [14][15].

华熙生物的下场无疑将"战况"再度升级，叠加此前，华熙生物炮轰"玻尿酸过时论"，华熙生物的此番下场战队，也被市场解读为是护肤成分市场中玻尿酸与 重组胶原蛋的路线之争。 出品｜搜狐财经 作者｜冯圆圆 端午假期期间，巨子生物产品造假风波再度升级。 6月1日晚间，华熙生物发文表示支持大嘴博士维护消费者权益；同时，已对大嘴博士发来的相关资料进行评估和第三方测试，且已得到结果。并表示，在其 公布结果之前，希望相关企业主动面对问题。 另一方面，巨子生物也在3小时后，发布了机构的道歉声明，同时表示对某上市公司的发言感到震惊又痛心。 一来一往，双方的发言均将矛头指向了对方。 可复美造假事件再升级 6月2日，知名大V大嘴博士再度发文"炮轰"巨子生物，剑指巨子生物对其合作的检测机构施压；同时表示，自己已联系不到当时负责检测的负责人。 （图片来源：大嘴博士颜究所） 大嘴博士的此番言论，再度将双方的"骂战"升级。 回顾时间线，5月24日，知名大V大嘴博士在微博发布了一则8分钟的视频，直指巨子生物旗下大单品可复美胶原蛋白精华的胶原蛋白含量造假。 （图片来源：大嘴博士微博） 据大嘴博士表示，巨子生物大单品可复美胶原蛋白精华中重组胶原蛋白的 ...

Policy Developments - The State Administration for Market Regulation announced ten typical cases of illegal advertising, with multiple cases involving the medical field, including one case related to medical device advertising and two cases concerning illegal drug advertising [2] - As of the end of April, a total of 11,459 illegal advertising cases were investigated, resulting in fines totaling 88.309 million yuan [2] Drug and Device Approvals - Shuyou Shen announced that its subsidiary received a notice from the National Medical Products Administration regarding the conditional listing application for "STSP-0601," a drug aimed at promoting rapid hemostasis for adult patients with hemophilia A or B [4] - Lepu Medical received registration approval from the NMPA for its self-developed polylactic acid facial filler, known as "童颜针," marking a significant milestone in the dermatology field [5] Capital Market Activities - Baiyang Pharmaceutical announced the release of 5.3 million shares from pledge by its controlling shareholder, representing 1.44% of the shares held by the shareholder and 1.01% of the company's total share capital [7] - Jincheng Pharmaceutical provided a guarantee of 5 million yuan for its wholly-owned subsidiary, Shandong Jincheng Biological Pharmaceutical Co., Ltd. [8] Industry Developments - AstraZeneca announced significant progress in the treatment of EGFR mutation-positive non-small cell lung cancer with MET amplification, with interim results from the SACHI Phase III study to be presented at the ASCO annual meeting [10][11] - Yuheng Pharmaceutical signed a market promotion service agreement with Eisai (China) Pharmaceutical for "Mikobao," which will enhance Yuheng's product pipeline and increase revenue [12] - New Scene Intelligence authorized BeiGene to develop universal cell therapy drugs based on a specific TCR molecule, with potential milestone payments and revenue sharing [13] - Buchang Pharmaceutical withdrew its clinical trial application for a rabies vaccine, indicating the need for further research before resubmission [14] Public Opinion Alerts - Huaxi Biological responded to recent controversies regarding recombinant collagen, emphasizing the importance of product quality over naming conventions [16] - Kangning Jerey announced a share transfer agreement involving 14.6 million shares, amounting to 117 million HKD [17]

// 今日关注 // 1 、 5 月财新中国制造业 PMI 降至 48.3 ，去年 10 月以来首次收缩 2 、经合组织将 2025 年全球 GDP 增长预期下调至 2.9% 3 、商务部新闻发言人就欧盟拟限制中企参与医疗器械公共采购答记者问 4 、全国工商联汽车经销商商会倡议，坚决抵制 " 内卷式 " 竞争 5 、国内成品油价迎年内 " 第四涨 " 6 、摸排股市 " 小作文 " ，地方证监局在行动 7 、 AI 教父警告：新一代大模型开始 " 撒谎 " // 宏观预警 // 1 、 5 月财新中国制造业 PMI 降至 48.3 ，去年 10 月以来首次收缩 5 月财新中国制造业采购经理指数（ PMI ）录得 48.3 ，较 4 月下降 2.1 个百分点， 2024 年 10 月来首 次跌至临界点以下。其中生产指数和新订单指数均从扩张区间降至收缩区间，分别录得 2022 年 12 月和 2022 年 10 月以来最低。 2 、经合组织将 2025 年全球 GDP 增长预期下调至 2.9% 经合组织将 2025 年全球 GDP 增长预期下调至 2.9% （之前为 3.1% ），同时将 2026 年的预期从 3 ...

2、 美国总统特朗普宣布将进口钢铁和铝及其衍生制品的关税从25%提高至50%， 该关税政策自美国东部时间2025年6月4日凌晨00时01分起生效。 美国 从英国进口的钢铝关税仍将维持在25%。 3、当地时间6月4日， 韩国中央选举管理委员会召开全体会议，表决通过了大选投票结果的议案，李在明当选韩国第21届总统，任期自当地时间6月4日6 时21分正式开始。 根据计票结果，共同民主党候选人李在明的得票率为49.42%，国民力量党候选人金文洙得票率为41.15%，改革新党候选人李俊锡得票 率为8.34%。 4、 日本10年期国债拍卖爆了。 据日本财务省发布的数据，在周二2.6万亿日元10年期国债的拍卖中，投标倍数从上月的2.54大幅跃升至3.66，拍卖需求关 键指标升至2024年4月以来最高水平。受此影响， 日本中长期政府债券价格直线拉升，10年期国债收益率一度跌3.5个基点至1.47%。 有分析警告称，虽然 10年期国债拍卖结果超出预期暂时缓解了市场紧张情绪，但市场真正的考验将是周四举行的30年期国债拍卖。 1、 外交部就"白宫称中美元首本周将通话"表示，没有可以提供的消息。 2、国务院总理李强会见日本国际贸易促 ...

2025年6月4日 星期三 ↓ 今日有2155亿元7天期逆回购到期 2国家卫生健康委定玉今日召开新闻 绍提升全民健康素养有关情况，并答 3 美国5月ADP就业人数变动将公布 (4)美国5月Markit综合PMI终值将公 1 隔夜市场 美股三大指数集体收涨，道指涨0.51%，纳指涨0.81%，标普500指数涨0.58%，热门科技股多数上涨，博通涨超3%，英伟达涨超2%，英伟达超越微软，成 为全球市值最高的公司，这家人工智能芯片制造商的市值攀升至3.445万亿美元，超过微软的3.441万亿美元。计算机硬件、加密货币概念股涨幅居前，安森 美半导体涨超11%，纳微半导体涨超7%，超微电脑、Coinbase涨近5%，美光科技涨超4%，戴尔科技、希捷科技涨超3%，英特尔、AMD涨超2%。纳斯达克 中国金龙指数涨0.56%，热门中概股多数上涨，理想汽车涨超6%，爱奇艺涨超3%，拼多多、小鹏汽车涨近2%，哔哩哔哩跌超2%，京东跌超1%。 国际金价下挫，现货黄金跌0.83%，报3352.885美元/盎司；COMEX黄金期货跌0.60%，报3376.90美元/盎司；COMEX白银期货跌0.05%，报34.68美元/盎 司。 国际 ...